Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naïve metastatic breast cancer patients

European Journal of Cancer

Volumn 41, Issue 2, 2005, Pages 249-255

  Berruti, Alfredo ^a   Bitossi, Raffaella ^a   Bottini, Alberto ^b   Bonardi, Simone ^b   Donadio, Michela ^c   Nigro, Cinzia ^c   Bertetto, Oscar ^c   Danese, Saverio ^d   Bertone, Elena ^d   Sarobba, Maria Giuseppa ^e   Farris, Antonio ^e   Katsaros, Dionyssios ^d   Castiglione, Federico ^f   Volpe, Teresa ^d   Lattuada, Sara ^g   Mancarella, Sergio ^h   Dogliotti, Luigi ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b Ist Osp   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d Azienda Ospedaliera Materno Infantile OIRM SAnna   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f Ospedale S Lazzaro   (Italy)

^g SANT'ANDREA HOSPITAL   (Italy)

^h Oncologia Medica   (Italy)

Author keywords

5 Fluorouracil; Breast cancer; Epirubicin; Metastatic disease; Vinorelbine

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIRUBICIN; FLUOROURACIL; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLADDER DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; PRIORITY JOURNAL; SKIN TOXICITY; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; VINBLASTINE;

EID: 19944430888     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.003     Document Type: Article

References (30)

1. E. Negri, C. La Vecchia, and A. Decarli Cancer mortality in Italy, 1997: quantifying the fall in rates in women and men Tumori 87 2001 290 298
2. J. Crown, V. Diéras, and M. Kaufman Chemotherapy for metastatic breast cancer-report of a European expert panel Lancet Oncol. 3 2002 719 726
3. G. Bonadonna, L. Gianni, and A. Santoro Drugs ten years later: epirubicin Ann. Oncol. 4 1993 359 369
4. J.M. Nabholtz, G. Falkson, and D. Campos Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J. Clin. Oncol. 21 2003 968 975
5. J. Jassem, T. Pienkowski, and A. Pluzanska Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J. Clin. Oncol. 19 2001 1707 1715
6. V. Valero, and G. Hortobagyi Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J. Clin. Oncol. 21 2003 959 962
7. A. Fellous, R. Ohayon, and T. Vacassin Biochemical effects of Navelbine on tubulin and associated proteins Semin. Oncol. 16 Suppl 4 1989 9 14
8. P. Vici, G. Colucci, and V. Gebbia First-line treatment with epirubicin and vinorelbine in metastatic breast cancer J. Clin. Oncol. 20 2002 2689 2694
9. C. Nisticò, C. Garufi, and S. Barni Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer Ann. Oncol. 10 1999 937 942
10. M. Spielman, T. Dorval, and F. Turpin Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer J. Clin. Oncol. 12 1994 1764 1770
11. B. Norris, K.I. Pritchard, and K. James Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol. 18 2000 2385 2395
12. M. Venturini, A. Durando, and O. Garrone Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breasst carcinoma Cancer 97 2003 1174 1180
13. J.Y. Pierga, M. Jouve, and B. Asselain Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90) Br. J. Cancer 77 1998 1474 1479
14. A.L. Jones, I.E. Smith, and M.E. O'Brien Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and local advanced breast cancer: an active new regimen J. Clin. Oncol. 12 1994 1259 1265
15. H. Gabra, D.A. Cameron, L.E. Lee, J. Mackay, and R.C. Leonard Weekly doxorubicin and continuous infusional 5-fluorouracil in advanced breast cancer Br. J. Cancer 74 1996 2008 2012
16. T. Eisen, I.E. Smith, and S. Johnston Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer J. Clin. Oncol. 16 1998 1350 1357
17. F. Recchia, S. De Filippis, and M. Rosselli Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer Am. J. Clin. Oncol. 24 2001 392 396
18. R.H. De Boer, T.G. Eisen, and P.A. Ellis A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer Ann. Oncol. 13 2002 889 894
19. A.C. Humphreys, J. Dent, and S. Rodwell Phase II study of docetaxel in combination with epirubicin and protracted venous infusion of 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study Br. J. Cancer 90 2004 2131 2134
20. A. Berruti, P. Sperone, and A. Bottini Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines J. Clin. Oncol. 18 2000 3370 3377
21. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
22. P. Therasse, S.G. Arbruck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J. Natl. Cancer Inst. 92 2000 205 216
23. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin. Trials 10 1989 1 10
24. R. Fossati, C. Confalonieri, and V. Torri Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women Clin. Oncol. 16 1998 3439 3460
25. C. Nistico, C. Garufi, and M. Milella Weekly epirubicin plus lonidamine in advanced breast carcinoma Breast Cancer Res. Treat 56 1999 233 237
26. G. Van Andel, P. Fernandez de Moral, and C.T. Caris A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life World J. Urol. 21 2003 177 182
27. Z.U. Rahman, D.K. Frye, and T.L. Smith Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy Cancer 85 1999 104 111
28. J.Y. Pierga, B. Asselain, and M. Jouve Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy Cancer 91 2001 1079 1089
29. E.F. Solomayer, I.J. Diel, G.C. Meyberg, C. Gollan, and G. Bastert Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Res. Treat 59 2000 271 278
30. L. Dogliotti, A. Berruti, and T. Buniva Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial J. Clin. Oncol. 14 1996 1165 1172